Showing results (91-100 of 106) with videos related to

Sort By:
Pageof 11
Asian Journal of Psychiatry|June 6, 2022
Characteristics of the treatments for each severity of major depressive disorder: A real-world multi-site studyHiroyuki Muraoka, Fumitoshi Kodaka, Naomi Hasegawa, et al.
Journal of Clinical Psychopharmacology|May 22, 2023
Combination Psychotropic Use for Schizophrenia With Long-Acting Injectable Antipsychotics and Oral Antipsychotics: A Nationwide Real-World Study in JapanToshiaki Onitsuka, Tsuyoshi Okada, Naomi Hasegawa, et al.
Brain, Behavior, and Immunity|March 10, 2024
Oxytocin-induced increases in cytokines and clinical effect on the core social features of autism: Analyses of RCT datasetsTomoyasu Wakuda, Seico Benner, Yukari Uemura, et al.
Neuropsychopharmacology Reports|November 17, 2022
Development of an individual fitness score (IFS) based on the depression treatment guidelines of in the Japanese Society of Mood DisordersKentaro Fukumoto, Fumitoshi Kodaka, Naomi Hasegawa, et al.
Brain : a Journal of Neurology|January 24, 2022
Effect of a novel nasal oxytocin spray with enhanced bioavailability on autism: a randomized trialHidenori Yamasue, Masaki Kojima, Hitoshi Kuwabara, et al.
Molecular Psychiatry|November 30, 2019
White matter microstructural alterations across four major psychiatric disorders: mega-analysis study in 2937 individualsDaisuke Koshiyama, Masaki Fukunaga, Naohiro Okada, et al.
Annals of General Psychiatry|December 25, 2022
The characteristics of discharge prescriptions including pro re nata psychotropic medications for patients with schizophrenia and major depressive disorder from the survey of the "Effectiveness of guidelines for dissemination and education in psychiatric treatment (EGUIDE)" projectYoshitaka Kyou, Norio Yasui-Furukori, Naomi Hasegawa, et al.
Frontiers in Psychiatry|June 3, 2022
Prescription of Anticholinergic Drugs in Patients With Schizophrenia: Analysis of Antipsychotic Prescription Patterns and Hospital CharacteristicsHikaru Hori, Norio Yasui-Furukori, Naomi Hasegawa, et al.
Neuropsychopharmacology Reports|October 18, 2022
Development of individual fitness score for conformity of prescriptions to the "Guidelines For Pharmacological Therapy of Schizophrenia"Ken Inada, Kentaro Fukumoto, Naomi Hasegawa, et al.
Neuropsychopharmacology Reports|February 26, 2025
Proposal for a Novel Classification of Patients With Enlarged Ventricles and Cognitive Impairment Based on Data-Driven Analysis of Neuroimaging Results in Patients With Psychiatric DisordersYuka Yasuda, Satsuki Ito, Junya Matsumoto, et al.
Pageof 11